MedPage Today -- The novel once-weekly injectable GLP-1 receptor agonist taspoglutide was better at improving glycated hemoglobin after six months than twice-daily exenatide (Byetta) -- but was plagued by the same gastrointestinal side effects that halted the T-Emerge series of trials, researchers said here.
